Kenvue, a spinoff of Johnson & Johnson, faces new accusations from President Trump regarding their Tylenol product and its alleged link to autism. Despite the negative press, the company is standing firm and disputing the claims. Kenvue stock has struggled, down over 30% year to date. The company, known for brands like BAND-AID and Neutrogena, has a market cap of $28.7 billion. While earnings have declined, Kenvue has been beating estimates and generating strong cash flow. Analysts are cautiously optimistic about KVUE stock, with a mean target price indicating potential upside of 32%.

Read more at 1. Global stocks plunge as concerns over inflation and rising interest rates grow. Barchart.

2. Tesla reports record-breaking profits in the first quarter of 2021, exceeding expectations. Barchart.

3. Amazon announces plans to hire 75,000 new employees in the U.S. and Canada, citing increased demand. Barchart.

4. Bitcoin reaches a new all-time high, surpassing $60,000 as institutional interest grows. Barchart.: Tylenol-Maker Kenvue’s Stock Is Down 30% in 2025. Its Fate May Be in the FDA’s Hands.